Contributions
Abstract: P564
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 21 Imaging
Background: Selective patterns of central nervous system atrophy have been investigated to distinguish neuromyelitis optica spectrum disorder (NMOSD) from multiple sclerosis (MS), and have been correlated with disability as determined by the expanded disability status scale (EDSS). However, many studies have been limited by a small sample size, especially for NMOSD. Additionally, there have been conflicting results in the previous studies that investigated the different pathological processes in regional brain structures between NMOSD and MS. Thus, here, we compare regional brain structures, such as cerebellum, brainstem and ventricles, between a large NMOSD cohort, relapsing-remitting MS (RRMS) and healthy controls.
Objective: To compare the volumes of various brain structures in a large NMOSD cohort compared to RRMS and healthy controls, and examine the correlation between volumes and EDSS.
Methods: T1-weighted MRIs (3T) were analyzed in 52 RRMS patients (mean age: 36 (range: 19-50); median EDSS: 2 (range: 0-6.5)), 91 NMOSD patients (34 (20-48); 2(0-7)), and 42 healthy controls (HC) (38 (20-49)). Brain structures were segmented using the FreeSurfer pipeline and normalized for intracranial volume. Group differences were calculated using one-way analysis of variance and Tukey's test.
Results: Brainstem (MS: 0.013±0.002; NMOSD: 0.014±0.002; HC: 0.014±0.001) and cerebellar (MS: 0.09±0.01; NMOSD: 0.09±0.01, HC: 0.09±0.01) volumes did not significantly differ between any of the groups. Lateral ventricle volume in MS (0.017±0.007) was significantly greater than in NMOSD (0.012±0.006) or in HC (0.009±0.004) (p< 0.0001). There was no significant difference between NMOSD and HC. Third ventricle volume was significantly different between all groups (MS: 0.0010±0.0004, NMOSD: 0.0008±0.0003, HC: 0.0006±0.0002) (p< 0.0001). Fourth ventricle volume showed a similar trend (MS: 0.0014±0.0005; NMOSD: 0.0013±0.0004; HC: 0.0011±0.0003), but only significantly between MS and HC (p=0.008). EDSS only correlated with lateral ventricle volume and only in NMOSD
(Pearson correlation coefficient=0.23, p=0.03).
Conclusion: Third ventricle volume may be most sensitive in detecting differences between MS, NMOSD and HC. In this large cohort of NMOSD patients, regional atrophy in NMOSD appears less affected than in MS, suggesting that NMOSD damage may be more localized.
Disclosure:
Emilie Russell has nothing to disclose.
Lisa Eunyoung Lee has nothing to disclose.
Anne Matthies has nothing to disclose.
Irene Vavasour has nothing to disclose.
Roger Tam has nothing to disclose.
Lisa Y.W. Tang has nothing to disclose.
Su-Hyun Kim has nothing to disclose.
Anthony Traboulsee consulting: Biogen, Roche, EMD Serono, Teva Pharmaceuticals; research support: Biogen, Chugai, CIHR, Roche, Michael Smith Foundation, MS Society of Canada
Ho Jin Kim has lectured, consulted, and received honoraria from Bayer Schering Pharma, Biogen, Genzyme, HanAll BioPharma, MedImmune, Merck Serono, Novartis, Teva-Handok, and UCB; received a grant from the Ministry of Science, ICT & Future Planning; and accepted research funding from Genzyme, Kael-GemVax, Merck Serono, Teva-Handok, and UCB; serves on a steering committee for MedImmune; is a co-editor for the Multiple Sclerosis Journal - Experimental, Translational, and Clinical, and an associated editor for the Journal of Clinical Neurology.
Shannon Kolind consulting: Acorda, Genzyme; research support: Roche, MS Society of Canada
Abstract: P564
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 21 Imaging
Background: Selective patterns of central nervous system atrophy have been investigated to distinguish neuromyelitis optica spectrum disorder (NMOSD) from multiple sclerosis (MS), and have been correlated with disability as determined by the expanded disability status scale (EDSS). However, many studies have been limited by a small sample size, especially for NMOSD. Additionally, there have been conflicting results in the previous studies that investigated the different pathological processes in regional brain structures between NMOSD and MS. Thus, here, we compare regional brain structures, such as cerebellum, brainstem and ventricles, between a large NMOSD cohort, relapsing-remitting MS (RRMS) and healthy controls.
Objective: To compare the volumes of various brain structures in a large NMOSD cohort compared to RRMS and healthy controls, and examine the correlation between volumes and EDSS.
Methods: T1-weighted MRIs (3T) were analyzed in 52 RRMS patients (mean age: 36 (range: 19-50); median EDSS: 2 (range: 0-6.5)), 91 NMOSD patients (34 (20-48); 2(0-7)), and 42 healthy controls (HC) (38 (20-49)). Brain structures were segmented using the FreeSurfer pipeline and normalized for intracranial volume. Group differences were calculated using one-way analysis of variance and Tukey's test.
Results: Brainstem (MS: 0.013±0.002; NMOSD: 0.014±0.002; HC: 0.014±0.001) and cerebellar (MS: 0.09±0.01; NMOSD: 0.09±0.01, HC: 0.09±0.01) volumes did not significantly differ between any of the groups. Lateral ventricle volume in MS (0.017±0.007) was significantly greater than in NMOSD (0.012±0.006) or in HC (0.009±0.004) (p< 0.0001). There was no significant difference between NMOSD and HC. Third ventricle volume was significantly different between all groups (MS: 0.0010±0.0004, NMOSD: 0.0008±0.0003, HC: 0.0006±0.0002) (p< 0.0001). Fourth ventricle volume showed a similar trend (MS: 0.0014±0.0005; NMOSD: 0.0013±0.0004; HC: 0.0011±0.0003), but only significantly between MS and HC (p=0.008). EDSS only correlated with lateral ventricle volume and only in NMOSD
(Pearson correlation coefficient=0.23, p=0.03).
Conclusion: Third ventricle volume may be most sensitive in detecting differences between MS, NMOSD and HC. In this large cohort of NMOSD patients, regional atrophy in NMOSD appears less affected than in MS, suggesting that NMOSD damage may be more localized.
Disclosure:
Emilie Russell has nothing to disclose.
Lisa Eunyoung Lee has nothing to disclose.
Anne Matthies has nothing to disclose.
Irene Vavasour has nothing to disclose.
Roger Tam has nothing to disclose.
Lisa Y.W. Tang has nothing to disclose.
Su-Hyun Kim has nothing to disclose.
Anthony Traboulsee consulting: Biogen, Roche, EMD Serono, Teva Pharmaceuticals; research support: Biogen, Chugai, CIHR, Roche, Michael Smith Foundation, MS Society of Canada
Ho Jin Kim has lectured, consulted, and received honoraria from Bayer Schering Pharma, Biogen, Genzyme, HanAll BioPharma, MedImmune, Merck Serono, Novartis, Teva-Handok, and UCB; received a grant from the Ministry of Science, ICT & Future Planning; and accepted research funding from Genzyme, Kael-GemVax, Merck Serono, Teva-Handok, and UCB; serves on a steering committee for MedImmune; is a co-editor for the Multiple Sclerosis Journal - Experimental, Translational, and Clinical, and an associated editor for the Journal of Clinical Neurology.
Shannon Kolind consulting: Acorda, Genzyme; research support: Roche, MS Society of Canada